EC Microbiology

The COVID-19 pandemic has profoundly impacted global health, with millions affected by SARSCoV-2. An increasing number of individuals experience persistent symptoms and complications long after the initial infection. Known as Long COVID or post-acute sequelae of SARS-CoV-2 infection (PASC), this condition encompasses a wide range of physical and psychological manifestations that significantly impair patients' quality of life and functional capacity. This review summarizes the current understanding of Long COVID, including its clinical manifestations, management strategies, and prognosis. A comprehensive search of relevant databases was conducted, and key findings from recent studies are synthesized to provide insights into the pathophysiology, diagnosis, and treatment of this emerging condition. The implications of Long COVID for clinical practice and future research directions are also discussed.

 Keywords: COVID-19; SARS-CoV-2; Long COVID

1. Carfi A., et al. “Persistent symptoms in patients after acute COVID-19”. Journal of the American Medical Association6 (2020): 603-605.
2. Huang C., et al. “6-month consequences of COVID-19 in patients discharged from hospital: a cohort study”. The Lancet 10270 (2021): 220-232.
3. Lerner AM., et al. “Persistent symptoms among US adults after COVID-19 infection: A nationwide survey”. Open Forum Infectious Diseases 1 (2021).
4. Arnold DT., et al. “Long-term outcomes of survivors of COVID-19 in the UK: a prospective observational study”. The Lancet Respiratory Medicine 10 (2021): 1012-1021.
5. Goërtz YMJ., et al. “Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome?” ERJ Open Research 4 (2020): 00542-2020.
6. Townsend L., et al. “Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection”. PLOS ONE11 (2020): e0240784.
7. Davis HE., et al. “Characterizing long COVID in an international cohort: 7 months of symptoms and their impact”. EClinicalMedicine 38 (2021): 101019.
8. American Academy of Neurology. “Cognitive impairment in post-COVID-19 patients”. Neurology15 (2021).
9. Douaud G., et al. “Brain imaging before and after COVID-19 in UK Biobank”. medRxiv (2021).
10. Graham EL., et al. “Persistent neurologic symptoms and cognitive dysfunction in non-hospitalized Covid-19 “long haulers””. Annals of Clinical and Translational Neurology 5 (2021): 1073-1085.
11. Puntmann VO., et al. “Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from COVID-19”. JAMA Cardiology 11 (2020): 1265-1273.
12. Xie Y., et al. “Risks of mental health outcomes in people with covid-19: cohort study”. British Medical Journal 376 (2021): e068993.
13. Raman B., et al. “Longitudinal follow-up of lung function and radiographic changes in a cohort of patients with moderate COVID-19”. Thorax 10 (2021): 972-981.
14. Rogers JP., et al. “Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis”. The Lancet Psychiatry7 (2020): 611-627.
15. Mazza MG., et al. “Anxiety and depression in COVID-19 survivors: Role of inflammatory and clinical predictors”. Brain, Behavior, and Immunity 89 (2020): 594-600.
16. Taquet M., et al. “6-month neurological and psychiatric outcomes in 236,379 survivors of COVID-19: a retrospective cohort study using electronic health records”. The Lancet Psychiatry5 (2021): 416-427.
17. Chen Y., et al. “Inflammatory cytokine levels in patients with long COVID: A systematic review and meta-analysis”. Clinical Microbiology and Infection 5 (2021): 710-718.
18. Wang EY., et al. “Persistent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and B cell response in a patient with lymphoma”. Clinical Infectious Diseases 7 (2021): 1096-1099.
19. Consiglio CR., et al. “The immunology of multisystem inflammatory syndrome in children with COVID-19”. Cell 4 (2021): 968-981.e7.
20. Su Y., et al. “Multi-omics resolves a sharp disease-state shift between mild and moderate COVID-19”. Cell 6 (2020): 1479-1495.e20.
21. Cheung CC., et al. “Olfactory and gustatory dysfunction in coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis”. Otolaryngology–Head and Neck Surgery 4 (2021): 617-629.
22. Gaebler C., et al. “Evolution of antibody immunity to SARS-CoV-2”. Nature 7851 (2021): 639-644.
23. Peluso MJ., et al. “Effects of long-term post-acute sequelae of SARS-CoV-2 (PASC) on physical function, exercise capacity, and quality of life in patients”. PLOS ONE9 (2021).
24. Daynes E., et al. “Early experiences of rehabilitation for individuals post-COVID to improve fatigue, breathlessness, exercise capacity, and cognition - A cohort study”. Chronic Respiratory Disease 18 (2021): 147997312199663.
25. Brugliera L., et al. “Rehabilitation of COVID-19 patients”. Journal of Rehabilitation Medicine 4 (2020).
26. Barker-Davies RM., et al. “The Stanford Hall consensus statement for post-COVID-19 rehabilitation”. British Journal of Sports Medicine 16 (2020): 949-959.
27. Lenz EA., et al. “Low-dose naltrexone for the treatment of chronic pain and fatigue in Long COVID: A case series”. Journal of Pain Research 14 (2021): 1461-1468.
28. Ramakrishnan S., et al. “Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial”. The Lancet Respiratory Medicine 7 (2021): 763-772.
29. Alwan NA., et al. “Antihistamines for Long COVID: A potential treatment strategy”. Journal of Medical Virology 11 (2021): 5825-5826.
30. Lopez-Leon S., et al. “More than 50 long-term effects of COVID-19: a systematic review and meta-analysis”. Scientific Reports 1 (2021): 16144.
31. Mandal S., et al. “Post-COVID-19 global health strategies: The need for an intersectional approach to addressing COVID-19 sequelae”. Journal of Global Health 11 (2021): 03060.
32. Iqbal FM., et al. “Characteristics and predictors of acute and chronic post-COVID syndrome: A systematic review and meta-analysis”. Journal of Global Health 11 (2021): 05052.
33. PHOSP-COVID Collaborative Group. “Physical and mental health 12 months after COVID-19: prospective cohort study”. British Medical Journal 375 (2021).
34. Blomberg B., et al. “Long COVID in a prospective cohort of home-isolated patients”. Nature Medicine 9 (2021): 1607-1613.
35. Arnold DT., et al. “Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: results from a prospective UK cohort”. Thorax4 (2021): 399-401.
36. Sudre CH., et al. “Attributes and predictors of Long-COVID: analysis of COVID cases and their symptoms collected by the Covid Symptoms Study App”. Nature Medicine 4 (2021): 626-631.
37. Greenhalgh T., et al. “Management of post-acute COVID-19 in primary care”. British Medical Journal 370 (2020): m3026.
38. Lambert N., et al. “COVID-19 and the patient: Addressing the root causes of health inequities”. Journal of Medical Ethics 2 (2021).
39. Lambert N., et al. “COVID-19 survivors’ reports of the timing, duration, and health impacts of Long COVID”. Nature Medicine 4 (2021): 626-631.
40. Logue JK., et al. “Sequelae in adults at 6 months after COVID-19 infection”. JAMA Network Open 2 (2021): e210830.
41. Carfì A., et al. “Persistent symptoms in patients after acute COVID-19”. Journal of the American Medical Association6 (2020): 603-605.
42. Garrigues E., et al. “Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19”. Journal of Infection 6 (2020): e4-e6.
43. Goërtz YMJ., et al. “Development of the COVID-19 YELCITAS”. BMJ Open8 (2020).
44. Halpin SJ., et al. “Post-discharge symptoms and rehabilitation needs in survivors of COVID-19 infection: A cross-sectional evaluation”. Journal of Medical Virology 2 (2021): 1013-1022.
45. Huang C., et al. “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China”. The Lancet10223 (2020): 497-506.
46. Liang L., et al. “Early rehabilitation for severely impaired COVID-19 patients: A randomized controlled trial”. Annals of the American Thoracic Society 10 (2020).
47. Wynants L., et al. “Prediction models for diagnosis and prognosis of COVID-19: Systematic review and critical appraisal”. British Medical Journal 369 (2020): m1328.
48. Bell ML., et al. “Environmental determinants of long COVID risk: A systematic review”. Lancet Planetary Health 10 (2021).
49. Nalbandian A., et al. “Post-acute COVID-19 syndrome”. Nature Medicine 4 (2021): 601-615.
50. Tenforde MW., et al. “Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network”. Morbidity and Mortality Weekly Report 30 (2020): 993-998.
51. Del Rio C., et al. “Long-term health consequences of COVID-19”. Journal of the American Medical Association 17 (2020): 1723-1724.
52. Tabacof L., et al. “Post-acute COVID-19 syndrome negatively impacts health and wellbeing despite less severe acute infection”. Journal of Medical Virology 12 (2021): 5712-5723.
53. Montani D., et al. “Pulmonary vascular consequences of COVID-19: A complex disease with many unknowns”. European Respiratory Journal 1 (2021): 2002773.
54. Meyerowitz EA., et al. “Transmission of SARS-CoV-2: A review of viral, host, and environmental factors”. Annals of Internal Medicine 1 (2021): 69-79.
55. Sivan M., et al. “The self-report version and digital version of the COVID-19 Yorkshire Rehabilitation Scale (C19-YRS) for Long COVID assessment and monitoring”. Journal of Medical Internet Research 11 (2021).
56. Writing Committee for the COMEBACK Study Investigators. “Comprehensive Management of Patients After COVID-19: A consensus statement on post-acute sequelae of SARS-CoV-2 infection”. Chest4 (2021).
57. FitzGerald JM., et al. “Canadian Thoracic Society position statement on post-COVID-19 condition (Long COVID)”. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine3 (2021): 168-171.
58. Desai AD., et al. “Cardiovascular complications in long-haul COVID: A state-of-the-art review”. Journal of the American College of Cardiology 11 (2021): 1023-1032.
59. Bhadelia N. “Defining the post-acute sequelae of SARS-CoV-2 infection: What do we know, and where do we go from here?” Clinical Infectious Diseases 2 (2021).
60. Chandrashekar A., et al. “SARS-CoV-2 infection protects against rechallenge in rhesus macaques”. Science6505 (2020): 812-817.